Supplementary file 1_Comparative efficacy and safety of dual-combination vs. triple-combin

21 randomized controlled trials involving 17,669 patients compare dual and triple antihypertensive drug regimens. The meta-analysis, authored by Zhuoling Gong and updated in May 2026, found triple therapy reduced systolic blood pressure by an average of 5.98 mmHg and increased blood pressure control rates by 31%. Results are based on a systematic search of PubMed, Embase, Cochrane, and Web of Science up to July 2025.

Use Cases

• Compare blood pressure reduction efficacy between dual and triple drug regimens based on the reported weighted mean differences.
• Assess the safety profile of combination therapies based on the analysis of 14 adverse reaction symptoms.
• Investigate subgroup efficacy, such as valsartan-based triple therapy, for specific drug classes.
• Evaluate blood pressure control rates as a clinical outcome measure.
• Inform clinical guideline development with updated evidence on combination therapy.

Strengths

• Analysis includes 21 studies with a total of 17,669 patients, providing a substantial evidence base.
• Systematic search was conducted across four major databases (PubMed, Embase, Cochrane, Web of Science) up to July 2025.
• Specific quantitative results are reported, including weighted mean differences for blood pressure and relative risks for control rates and adverse events.

Limitations

• The underlying data file is a DOCX document (8.7 MB); column-level data structure and raw patient-level data are unavailable.
• The authors note significant heterogeneity in the results and caution that subgroup analyses are exploratory.
• Row count for any underlying tabular data is unknown, limiting suitability assessment for direct computational analysis.

Provenance

Source

figshare, author Zhuoling Gong.

Collection Method

Systematic review and meta-analysis of randomized controlled trials identified via database search.

Time Range

Studies included up to July 2025; analysis published May 2026.

Freshness

Last updated 2026-05-15 08:39:24.